Trial Profile
Phase 1b investigator initiated trial of combination therapy of Metformin and Nivolumab in participants with advanced or recurrent solid cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Dec 2023
Price :
$35
*
At a glance
- Drugs Metformin (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Thymic epithelial tumour
- Focus Adverse reactions; Pharmacokinetics
- 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress
- 02 Dec 2022 Planned End Date changed from 31 Dec 2022 to 31 Mar 2025.
- 30 Oct 2020 Planned End Date changed from 31 Dec 2020 to 31 Dec 2022.